Company Overview and News

3
Is The Bottom In For Celgene?

2018-08-14 seekingalpha
Celgene Corporation (CELG) has had a less than ideal past 10 months. Hitting highs in early October 2017 of $147.17, the stock fell to $74.13 in May 2018. A 50 percent drop, or a 50 percent pop, is standard for many of the smaller biotechs I cover, but not normally, the domain of a $60B biopharmaceutical giant like CELG. A lot of the factors that led to the drop of CELG are in the past now, and the focus of this article isn't to dwell on those.
CELGZ 524816 ARNA RDY NATCOPHARM CELG RCPT MS

1
Liquidia: Is It Worth Getting On Board Early?

2018-08-14 seekingalpha
Liquidia Technologies (LQDA) is a very interesting IPO story in 2018. The pharmaceutical upstart recently completed its IPO, with the stock going public at $11 per share. Over the past couple of weeks, shares have risen some 20% to $13 and change. Playing a stock on IPO can be a dangerous game, but as the dust begins to settle, the true story and true market cap of a company take shape. The question for those that did not get in on the IPO is whether it is still a good stock to buy.
MNKD ARNA UTHR LQDA

0
ARNA / Arena Pharmaceuticals, Inc. 8-K (Current Report)

2018-08-09 sec.gov
arna-8k_20180809.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION
ARNA

0
Arena Reports Loss As Expected - Pipeline Will Drive The Stock

2018-08-08 seekingalpha
The second quarter of 2018 seems like a "pause quarter" in the Arena Pharmaceutical (NASDAQ:ARNA) story. Essentially, the company seems to be well-positioned with a robust pipeline but will not have any "sexy" news to report for the next couple of quarters, absent a partnership or M&A activity.
ARNA

0
ARNA / Arena Pharmaceuticals, Inc. 10-Q (Quarterly Report)

2018-08-08 sec.gov
arna-10q_20180630.htm
ARNA

0
Arena Pharmaceuticals (ARNA) Q2 Loss Wider Than Expected

2018-08-07 zacks
Arena Pharmaceuticals, Inc. (ARNA - Free Report) reported a loss of 65 cents per share for the second quarter of 2018, wider than the Zacks Consensus Estimate of a loss of 62 cents. The year-ago loss was 77 cents per share.
SGEN ARNA VRTX GLPG

0
Arena Pharmaceuticals, Inc. (ARNA) CEO Amit Munshi on Q2 2018 Results - Earnings Call Transcript

2018-08-07 seekingalpha
Good day, everyone, and welcome to Arena Pharmaceuticals' Second Quarter 2018 Financial Results and Corporate Update Conference Call. This call is being recorded. [Operator Instructions]
ARNA CFN

0
ARNA / Arena Pharmaceuticals, Inc. 8-K (Current Report)

2018-08-06 sec.gov
arna-8k_20180806.htm UNITED STATES
ARNA

1
Pernix Therapeutics Buys Bankrupt Orexigen’s Weight Loss Drug for $73.5 Million

2018-07-31 biospace
In March, San Diego-based Orexigen Therapeutics filed for bankruptcy. Back in April, Orexigen entered into an asset purchase deal with Nalpropion Pharmaceuticals to sell most of its assets, subject to court approval. Under that deal, Orexigen would sell global rights to Contrave (naltrexone HCl/bupropion HCL extended release)/Mysimba (naltrexone HCl and bupropion HCL prolonged release) and other assets.
ARNA PTX

2
What's in the Cards for Arena (ARNA) This Earnings Season?

2018-07-27 zacks
Arena Pharmaceuticals, Inc. (ARNA - Free Report) is expected to report second-quarter 2018 earnings early next week.
ARNA ILMN HZNP

0
ARNA / Arena Pharmaceuticals, Inc. 8-K (Current Report)

2018-07-17 sec.gov
arna-8k_20180717.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION
ARNA

4
ARNA / Arena Pharmaceuticals, Inc. 8-K (Current Report)

2018-07-10 sec.gov
arna-8k_20180706.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION
ARNA

125
Liquidia To File IPO - What Investors Need To Know

2018-07-02 seekingalpha
Liquidia Technologies (LQDA), has filed the necessary paperwork with the SEC to make an initial public offering. The biopharma company is seeking to raise at least $57 million and will trade on the NASDAQ Capital Market. Jefferies and Cowen will run the book on the IPO.
MNKD ARNA GSK HRTX AERI UTHR INSM ALIOY GSK DRRX

44
Cara Therapeutics: Scratching An Itch Left Unscratched

2018-06-27 seekingalpha
CARA therapeutics wholly owns its proprietary kappa opioid-receptor agonist, KORSUVA/CR845, and is targeting several largely underserved markets.
ARNA CARA CRIS DRRX

321
A Short Case For A Longer Term!

2018-06-20 seekingalpha
Most investors should favor a longer-term time frame as the markets again record new highs after recovering from the first quarter pullback.
CRC ADAP ECYT LOXO NBIX ARWR SRPT TRXC CHGG SUPN RGNX ARNA TWLO IMMU NDAQ MRTX HEAR TTD

ARNA: Arena Pharmaceuticals Analysis and Research Report

2018-07-28 - Asif

Overview Arena Pharmaceuticals is a biopharmaceutical company focused on developing novel, small molecule drugs with optimized receptor pharmacology designed to deliver clinical utility across therapeutic areas. The company's proprietary, internally-developed pipeline includes multiple potentially first- or best-in-class programs. The company's three most advanced investigational clinical programs are: ralinepag (APD811), which Arena Pharmaceuticals is currently preparing for a Phase 3 program for pulmonary arterial hypertension, or PAH; etrasimod (APD334), which is being studied in Phase 2 trials for immune and inflammatory conditions with an initial focus on ulcerative colitis and hepatic conditions; and APD371 for visceral pain conditions and which is being studied in a Phase 2 trial for treatment of pain associated with Crohn's disease, or CD. In addition, Arena Pharmaceuticals has collaborations with the following pharmaceutical companies: Everest Medicines Limited (...

Related Articles

BLDP: Ballard Power Systems Analysis and Research Report

2018-08-13 - Asif

Core Business At Ballard, Ballard Power Systems is building a clean energy growth company. Ballard Power Systems is recognized as a world leader in proton exchange membrane (“PEM”) fuel cell power system development and commercialization. The company's principal business is the design, development, manufacture, sale and service of PEM fuel cell products for a variety of applications, focusing on its power product markets of Heavy-Duty Motive (consisting of bus, truck, rail and marine applications), Portable Power, Material Handling and Backup Power, as well as the delivery of Technology Solutions, including engineering services, technology transfer, and the license and sale of its extensive intellectual property portfolio and fundamental knowledge for a variety of fuel cell applications. A fuel cell is an environmentally clean electrochemical device that combines hydrogen fuel with oxygen (from the air) to produce electricity. The hydrogen fuel can be obtained from natural g...

MARA: Marathon Patent Group Analysis and Research Report

2018-08-13 - Asif

Overview Marathon Patent Group was incorporated in the State of Nevada on February 23, 2010 under the name Verve Ventures, Inc. On December 7, 2011, the company changed its name to American Strategic Minerals Corporation and were engaged in exploration and potential development of uranium and vanadium minerals business. In June 2012, the company discontinued its minerals business and began to invest in real estate properties in Southern California. In October 2012, the company discontinued its real estate business when its former CEO joined the firm and the company commenced its IP licensing operations, at which time the Company’s name was changed to Marathon Patent Group, Inc. On November 1, 2017, the company entered into a merger agreement with Global Bit Ventures, Inc. (“GBV”), which is focused on mining digital assets. Marathon Patent Group has since purchased its cryptocurrency mining machines and established a data center in Canada to mine digital assets. Following the me...

ECYT: Endocyte Analysis and Research Report

2018-08-13 - Asif

Business and Organization Endocyte, Inc. is a biopharmaceutical company and leader in developing targeted therapies for the treatment of cancer. The Company uses drug conjugation technology to create novel therapeutics and companion imaging agents for personalized targeted therapies. The agents actively target receptors that are over-expressed on diseased cells relative to healthy cells, such as prostate specific membrane antigen (“PSMA”) in prostate cancer. This targeted approach is designed to safely enable the delivery of highly potent drug payloads. The companion imaging agents are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment. In September 2017, the Company entered into a Development and License Agreement (the “License Agreement”) with ABX advanced biochemical compounds – Biomedizinische Forschungsreagenzien GmbH (“ABX”), pursuant to which the Company acquired exclusive ...

CUSIP: 040047102